Denmark’s economy was reshaped by Novo Nordisk and obesity drugs. That identity is now under attack on multiple fronts, from ...

Advances recognized by science’s most lucrative awards include high-energy physics experiments and groundbreaking weight-loss ...

A popular weight-loss drug used by celebrities overseas has been approved by New Zealand’s medicine regulatory body, with its ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

European markets are expected to open lower Monday as global markets await U.S. President Donald Trump’s previously announced ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo Nordisk has signed another obesity pact, this one for an oral drug that works via an uncommon mechanism and could potentially help patients maintain their weight loss when they stop taking ...

Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.

Under terms of the deal, Novo Nordisk will obtain global rights to develop ... Obesity Week 2024 demonstrated that when combined with semaglutide, LX9851 enhanced weight reduction, appetite ...

His calculations indicate that Zepbound is taking 59% of overall weekly prescriptions for weigh-loss medication vs. Novo Nordisk taking the remaining 41%. Perhaps more worrying for the European ...

Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...